Year: 2020
Type: dissertation
Abstract: Photodynamic therapy (PDT) relies on the administration of a photosensitizer (PS) that is activated on the target tissue after the irradiation with light of a specific wavelength absorbed by the PS. Redaporfin is a recently developed photosensitizer for PDT that is currently in phase 2 clinical trials (NCT02070432). Redaporfin is a photostable bacteriochlorin with intense infrared absorption, high yield of ROS generation, high phototoxicity, low skin photosensitivity and favorable pharmacokinetics. A vascular protocol of redaporfin-PDT with mice bearing CT26.WT tumors not only destroys the primary tumor but also reduces the development of metastasis, thus suggesting antitumor immunity. This work characterizes the immune response triggered by this vascular-PDT protocol. At different timepoints after tumor irradiation, blood samples were collected, and distinct immune cell populations and cytokines were quantified. Redaporfin-PDT leads to a strong neutrophilia, with systemic increase of IL-6, increased percentage of CD4+ and CD8+ T cells producing IFN-γ or CD69+ and increased CD4+/CD8+ T cell ratio. We also showed that at the tumor bed, T cell tumor infiltration disappeared after PDT but reappeared with a much higher incidence one day later. The depletion of specific immune populations suggested that neutrophils and cytotoxic T cells have a major role in the development of the antitumor immune response elicited by redaporfin-PDT, while helper T cells may just have a supportive role. Regarding this, we hypothesize that the combination of redaporfin-PDT with an immune therapy may potentiate the efficacy of both therapies, namely by increasing the response rates of immunotherapies and strengthening the systemic effects of PDT, especially in difficult tumors to treat. The tumor models were selected taking in consideration that redaporfin-PDT is capable of eliciting immunogenic cell death (ICD) and may be able to enhance the immunogenicity of tumor cells. Melanoma and mammary carcinoma tumors are recognized to be more aggressive and difficult to treat than most mouse tumor models, namely colon carcinoma. The response to redaporfin-PDT was evaluated in mouse mammary carcinoma expressing luciferase (4T1-luc2) and in mouse skin melanoma (B16F10) tumor models, and PDT parameters were optimized to maximize the impact on tumors while minimizing treatment lethality. A significant edema that later progressed to necrosis was observed in both tumor models. However, cures were only achieved with the B16F10 tumor model. Imaging with photoacoustic tomography suggested that the lower content of redaporfin in 4T1 tumors is the main reason for the challenging behavior of this orthotopic 4T1 model. The antitumor effect elicited by PDT is in some cases opposed by the immunosuppressive mechanisms elicited by tumor cells which makes the treatment ineffective. Thus, immunotherapies that have as major goal the alleviation of this immunosuppressive tumor environment are interesting for combination therapies, increasing the efficacy with better antitumoral and antimetastatic effects. We reported a combination of redaporfin-PDT with immunotherapies using CTLA-4 and PD-1 in three different tumor models. Treatment outcomes were evaluated by survival, tumor growth kinetics and, for the carcinoma model, observation of metastasis development by bioluminescent imaging. Furthermore, we evaluated the changes on expression of several immune checkpoint molecules triggered by redaporfin-PDT in vitro. Combination of redaporfin-PDT with CTLA-4 immunotherapy, but not with PD-1, led to a significant improvement of survival and a higher cure rate in the colon carcinoma animal model. However, the same was not achieved with the melanoma and breast carcinoma animal models. Expression of immune checkpoint molecules was induced in tumor cells treated in vitro with redaporfin-PDT. The most notable changes were observed for CD80 and PD-L1. These results demonstrate that the combination of photodynamic therapy with immunotherapy may improve the treatment of malignant diseases that represent a challenge to immunotherapies alone and highlights the fact that a global therapeutic strategy may not be ideal for every tumor model. Combinatorial approaches are not universal and have to be tailored to the specificities of each clinical case.
Author: Catarina S. Lobo
Institution: University of Coimbra
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W3186766689
